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Abstract
The role of 5-HT7 receptor has been demonstrated in various animal models of mood disorders; however its function in
cognition remains largely speculative. This study evaluates the effects of SB-269970, a selective 5-HT7 antagonist, in a
translational model of working memory deficit and investigates whether it modulates cortical glutamate and/or dopamine
neurotransmission in rats. The effect of SB-269970 was evaluated in the delayed non-matching to position task alone or in
combination with MK-801, a non-competitive NMDA receptor antagonist, and, in separate experiments, with scopolamine, a
non-selective muscarinic antagonist. SB-269970 (10 mg/kg) significantly reversed the deficits induced by MK-801 (0.1 mg/
kg) but augmented the deficit induced by scopolamine (0.06 mg/kg). The ability of SB-269970 to modulate MK-801-induced
glutamate and dopamine extracellular levels was separately evaluated using biosensor technology and microdialysis in the
prefrontal cortex of freely moving rats. SB-269970 normalized MK-801 -induced glutamate but not dopamine extracellular
levels in the prefrontal cortex. Rat plasma and brain concentrations of MK-801 were not affected by co-administration of SB-
269970, arguing for a pharmacodynamic rather than a pharmacokinetic mechanism. These results indicate that 5-HT7
receptor antagonists might reverse cognitive deficits associated with NMDA receptor hypofunction by selectively
normalizing glutamatergic neurotransmission.
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Introduction
The 5-HT7 receptor, a postsynaptic G protein coupled receptor
was identified in 1993 through a homology cloning strategy and
found to modulate positive cAMP formation via Gs[1]. In the
brain, 5-HT7 receptors are distributed in the suprachiasmatic
nucleus of the hypothalamus, hippocampus, cortex, thalamus and
raphe nuclei on GABAergic interneurons or on glutamate terminals
[1,2,3]. 5-HT7 receptor antagonists have been evaluated in several
animal models predictive of anxiolytic-and antidepressant-like
activity [3,4,5]. For example, blockade of 5-HT7 receptors in the
rat Vogel test increased the number of shocks [6]. In addition, mice
treated with 5-HT7 receptor antagonists as well as mice lacking the
5-HT7 receptors display decreased immobility time in the tail
suspension test [7,8,9,10]. These results suggest that blockade of 5-
HT7 receptors may have anxiolytic and antidepressant activity in
humans. 5-HT7 receptor antagonists have been also evaluated in
animal models predictive of antipsychotic-like activity. One hypoth-
esis of schizophrenia is based on N-methyl-D aspartic acid (NMDA)
receptor hypofunction. NMDA antagonists such as ketamine and
phencyclidine (PCP) induce hyperactivity, stereotypy and sensorimotor
gating deficits in multiple species including humans and they can
exacerbate positive symptoms of schizophrenia. Treatments with
atypical antipsychotic drugs are known to reverse these effects [11].
Preclinical studies have demonstrated that SB-258741, a selective 5-
HT7 receptor antagonist, blocked phencyclidine (PCP)-induced
hyperactivity in rats [12]. Furthermore, SB-269970, an analog of
SB-258741, partially but significantly blocked ketamine -induced
hyperactivity in mice [13]. In addition, PCP-induced prepulse inhi-
bition deficits were less pronounced in 5-HT7 knockout mice com-
pared to wild-type mice [14]. However, 5-HT7 receptor antagonists
did not reverse prepulse inhibition deficits in rats and mice [14].
Thus, the antipsychotic-like activity of selective 5-HT7 receptor
antagonists is weakerthan clinicallyprovenantipsychotic drugs[15].
However, current antipsychotics do not show strong efficacy in
cognitive deficit associated with psychiatric disorders including
depression and schizophrenia.
It is currently debated whether 5-HT7 receptor antagonists can
improve cognition [16]. Mice lacking the 5-HT7 receptor showed
impaired contextual fear conditioning but no significant deficits in
motor and spatial learning or cued and operant conditioning [17].
Animal studies with selective 5-HT7 receptor antagonists have
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maze task, 5-HT7 receptor blockade had a pro-cognitive effect,
when the learning task implicated a high degree of difficulty [18].
Another study showing that the 5-HT7 antagonist SB-269970 did
not have any effect on an associative learning task in normal
animals [19]. However, in the later study, SB-269970 reversed the
amnesic effect elicited by scopolamine (a non selective muscarinic
antagonist), MK-801 (dizocilpine, a non-competitive NMDA
receptor antagonist) andmCPP (m-chlorophenylpiperazine, a
non selective serotonin ligand) [19].
Altered acetylcholine neurotransmission induced by musca-
rinic antagonist (e.g. scopolamine) and hypofunction of NMDA
receptors induced by NMDA antagonists (e.g. MK-801) are asso-
ciated with cognitive-related deficits in many species including
humans [20,21]. For example, MK-801 and ketamine increase
errors in the 8-arm maze delayed-matching to position and
autoshaping learning task in rodents [19,22]. Similarly, in hu-
mans, NMDA receptor antagonists impair performance in the
Wisconsin Card Sort task as well as other cognitive models
[21,23,24,25]. NMDA antagonists increase both glutamate and
dopamine extracellular levels in the rat cortex, a brain region
critical in mediating cognitive-related responses, particularly
working memory and executive function which are impaired in
schizophrenic patients [26,27]. It is thought that NMDA antag-
onists produce schizophrenic-like reactions in humans by disr-
upting cortical networks and enhancing glutamate release.
Antipsychotics attenuate MK-801-induced glutamate release in
the cortex [28], which may mediate some aspects of their clinical
efficacy. It is also known that working memory performance is
highly dependent on an optimal amount of dopamine in the
prefrontal cortex, which tightly regulates network activity [29].
Thus, too little or too much dopamine interferes with working
memory performance. MK-801, which enhances dopamine re-
lease in the cortex, would thus be expected to interfere with
working memory, in part through an over-stimulation of the
cortical dopamine system and subsequent disruption to organized
network activity.
The goal of the present studies was two-fold: first, to evaluate
the effects of the selective 5-HT7 receptor antagonist SB-269970
[30], in a translational behavioral model of working memory.
The second goal was to evaluate, at a neurochemical level, the
effects of SB-269970 on cortical glutamate and dopamine extra-
cellular levels. Specifically, the effect of SB-269970 was evaluated
in rats using delayed non-matching to position (DNMTP), a
translational procedure that is thought to measure working
memory. In addition, the effects of SB-269970 on glutamate and
dopamine extracellular levels were evaluated using biosensor
technology (glutamate) and microdialysis (dopamine) in freely
moving rats. A pharmacokinetic study was also carried out to
determine plasma and brain concentrations of MK-801 after co-
administration of SB-269970 to investigate a potential drug-drug
interaction.
Methods
Ethics Statements
All animal experiments were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publications No. 8023, revised 1978)
and were approved by the Institutional Animal Care and Use
Committee (IACUC) at Johnson & Johnson Pharmaceutical
Research & Development, L.L.C., San Diego (microdialysis
protocol #1048, behavior protocol #100063, pharmacokinetics
protocol # 1000117).
Drugs
SB-269970 hydrochloride ((2R)-1-[(3-hydroxyphenyl)sulfonyl]-
2-[2-(4-methyl-1-piperidinyl)ethyl]-pyrrolidine) was purchased
from Tocris Bioscience (Ellisville, MO). MK-801 ((5S,10R)-(+)-
5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine
maleate) and scopolamine were purchased from Sigma Aldrich
(St. Louis, MO). All compounds were dissolved in saline (SB-
269970, MK-801) or water (scopolamine). Doses are expressed as
mg/kg of free base (volume of injection =1 ml/kg).
Delayed non-matching to position (DNMTP) task
Sprague-Dawley rats (Harlan, Indianapolis, Ind., USA, 250–
300 g upon arrival) were maintained at 80–90% of their free
feeding weight. All animals were single-housed in plastic cages
under a 12h:12hlight:dark schedule in humidity controlled rooms
and had ad libitum access to water. Animals were trained to
respond for food in sound attenuating operant chambers (Med-
Associates, St Albans, VT). Chambers were equipped with two
levers with stimulus lights and a food hopper. Each test session
lasted 30 min and started with the illumination of the house-light
and the random presentation of one lever. When the animal
pressed the lever, it was immediately retracted for up to a random
period of time (0, 4, 8, 16, or 32 sec delay). At the end of the delay
both levers were presented. Pressing the lever which was not
initially presented (i.e. correct response) resulted in the illumina-
tion of both stimulus lights for 1 s, the delivery a 45 mg food pellet
(Bio-Serv, Frenchtown, NJ, USA), and the end of the trial.
Pressing the lever that was initially presented (incorrect response)
resulted in the retraction of both levers and the end of the trial. At
the end of the trial, a new trial with a new random delay was
initiated. SB-269970 (10 mg/kg) and scopolamine (0.06 mg/kg),
or their vehicles, were administered intraperitoneally at 10 and
30 min, respectively, before the beginning of the session. SB-
269970 (10 mg/kg) and MK-801 (0.1 mg/kg), or their vehicles,
were co-administered intraperitoneally at 10 min before the
beginning of the session. The dose of MK-801 was chosen based
on pilot studies showing impaired working memory without
producing gross psychostimulant effects that would interfere with
lever pressing. Each experiment was conducted in a Latin-square
design with washout periods between each drug test (N=6). Data
from each experiment were analyzed for percent correct choices
with a two-way analysis of variance (ANOVA) for treatment group
x delay, with repeated measures on delay, followed by Duncan’s
post-hoc tests when appropriate. The number of trials completed
during each session was analyzed using a one-way repeated
measures ANOVA for treatment group. Statistica (StatSoft Inc.,
Tulsa OK) was used for data analysis.
Real-time measurements of glutamate efflux in the
cortex of freely moving rats
Male Sprague-Dawley rats (Charles River Laboratories) weigh-
ing 280–350 grams were used. All animals were single-housed in a
12h:12hlight:dark schedule in humidity controlled rooms and had
ad libitum access to water. Each rat was given a subcutaneous
0.05 mL injection of Buprenex (buprenorphine hydrochloride;
Reckitt Benckiser Pharmaceuticals Inc., Richmond, VA) at
0.06 mg/kg 5 minutes prior to anesthesia. Animals were
anesthetized with an Isoflurane/air mixture and stereotaxically
implanted with a guide cannula (BAS) in the prefrontal cortex
(incisor bar, 23.5 mm, 3.2 mm anterior, 0.9 mm lateral and
2 mm ventral to Bregma, [31]. The guide cannula and bone
screws were encased with acrylic dental cement. Animals were
allowed at least 5 days to recover from surgery prior to
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mentation occurred within the animal’s home cage.
The glutamate biosensor (wireless model 7001, Pinnacle
Technologies, Lawrence KS) specification and hardware setup
was described previously [32]. Prior to sensor insertion, each
biosensor was calibrated in-vitro to verify glutamate sensitivity and
interference rejection. The morning of experimentation, under
light isoflurane anesthesia, the biosensor was inserted into the pre-
frontal cortex. Experimentation began once a stable sensor signal
was obtained, approximately 4 hours. At the completion of the
experiment, each sensor was removed from the guide cannulae
and calibrated in vitro for glutamate sensitivity and interference
rejection of ascorbate at 37uC in a circulating water bath.
Initially, all 15 animals received an intraperitoneal vehicle injec-
tion. Sixty min later, they received the following intraperitoneal
treatments: vehicle + MK-801, 0.1 mg/kg (N=5), SB-269970,
10 mg/kg + MK-801, 0.1 mg/kg (N=5) or SB-269970, 10 mg/
kg + vehicle (N=5).
Following experimentation the data was exported to excel and
binned into 5 minute current (nA) intervals. These data points
were then converted to glutamate concentrations using calibration
curve regression data for the corresponding sensor.
Statistical analyses were performed on the change in glutamate
concentrations with a two-way ANOVA for treatment x time, with
repeated measures on time, followed by Duncan’s post-hoc tests.
Statistics were calculated using Statistica (StatSoft Inc., Tulsa OK).
Dopamine microdialysis in the cortex of freely moving rats
Male Sprague-Dawley rats (Charles River Laboratories) weigh-
ing 280–350 grams were used. All animals were single-housed in a
12h:12hlight:dark schedule in humidity controlled rooms and had
ad libitum access to water. Each rat was given a 0.05 ml SC
injection of Buprenex 0.06 mg/kg (buprenorphine hydrochloride)
5 mins prior to anesthesia. Animals were anesthetized with an
isoflurane/air mixture and stereotaxically implanted with a guide
cannulae (Eicom) in the prefrontal cortex (incisor bar 23.5 mm,
+3.2 mm anterior, 0.8 mm lateral and 1 mm ventral to Bregma)
[31]. The guide cannula was secured in place with skull screws and
dental cement. Animals were allowed at least 3 days to recover
from surgery prior to experimentation.
Dialysis experiments were conducted as previously described
[33]. Dialysate was analyzed by high-performance liquid chroma-
tography with an electrochemical detector (Eicom HPLC/EC).
The dopamine concentration for each sample was calculated from
the peak area of the chromatographic signal and the slope from
the corresponding standard curve.
A between subject design was used. The following conditions
were evaluated: vehicle + vehicle (N=5), vehicle + MK-801,
0.1 mg/kg (N=6), SB-269970, 10 mg/kg + MK-801, 0.1 mg/kg
(N=5) and SB-269970, 10 mg/kg + vehicle (N=5). All com-
pounds were administered intraperitoneally.
The percent change from baseline values were calculated from
the mean basal value of each neurotransmitter for each animal
and presented in the figures as mean 6 S.E.M.
Statistical analyses were performed on the percent baseline with
a two-way ANOVA for treatment x time, with repeated measures
on time, followed by Duncan’s post-hoc tests. Statistics were
calculated using Statistica (StatSoft Inc., Tulsa OK).
At the end of the experiments, microdialysis and biosensor
probe placement was visually verified for each animal. Brains were
removed, frozen and sectioned with a microtome to verify probe
placement. Only animals with correct placement of the probe were
used for data analysis.
Pharmacokinetics and bioanalysis
Male Sprague-Dawley rats (Charles River Laboratories) weigh-
ing 300–350 grams were used. Intraperitoneal dosing (vehicle
+0.1 mg/kg MK-801 or 10 mg/kg SB-269970 +0.1 mg/kg MK-
801; N=4 per group) was followed by blood sampling via cardiac
puncture over a time course. Brains were removed from the
animals and homogenized for LC/MS-MS analysis. All blood
samples were deproteinized by 1:4 dilution of the sample with
acetonitrile with vigorous mixing. These samples were incubated
for 5 minutes, and then centrifuged at 14,000 rpm in a micro-
centrifuge for 4 minutes. The supernatant was recovered into
auto-sampler vials and diluted 1:1 with sterile water. Samples were
analyzed by LC-MS/MS. A Vydac SP C18 2.1650 mm analytical
column was used for separation.
Statistics (paired t-test) were calculated using Prism software
(GraphPad, San Diego, CA). The level of significance was p,0.05.
A one compartmental pharmacokinetic model was applied to
these data using the software package WinNonlin Version 4.0.1.
(Pharsight, Palo Alto, Ca). A one compartment first order, no lag
time, first order elimination model (Model 3) was employed. The
parameters of the model were optimized using least squares non-
linear regression. Pharmacokinetic and blood brain barrier
penetration parameters are given as the means 6 coefficient of
variation. The coefficient of variation is a measure of dispersion of
a probability distribution. It is defined as the ratio of the standard
deviation to the mean. The coefficient of variation was calculated
as the ratio of the standard error for each parameter to its
estimated value.
Results
SB-269970 blocks MK-801 induced deficits in the DNMTP
task
The effect of SB-269970 (10 mg/kg, IP) on MK-801 (0.1 mg/kg,
IP) induced deficits was evaluated in the DNMTP task (Fig. 1). The
number of trials completed for each group is given in Table 1. A two-
way repeated measures ANOVA (delay x treatment group), with
repeated measures on group, detected a main effect of delay (F(4,
25)=5.99, p=0.0016) and group (F(3, 75)=15.49, p=0.000005),
Figure 1. Effects of SB-269970 on MK-801-induced DNMTP
deficits. SB-269970 (10 mg/kg) and MK-801 (0.1 mg/kg), or their
vehicles, were co-administered 10 min before the beginning of the
session (N=6 per group). SB-269970 had no effect on its own but
reversed the deficit caused by MK-801 (*p,0.05, main effect). For
statistical details see the result section.
doi:10.1371/journal.pone.0020210.g001
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on group revealed that MK-801 worsened performance (p,0.00005
comparing vehicle + vehicle to vehicle + MK-801). SB-269970 had
no effect on its own (p=0.68, comparing vehicle + vehicle to SB-
269970 + vehicle), but reversed the deficit caused by MK-801
(p,0.0002 comparing vehicle + MK-801 to SB-269970 + MK-801)
so that the SB-269970 + MK-801 group was no different from the
SB-269970 + vehicle group (p=0.70). There was no difference in the
number of trials completed in each session among treatment groups
(F(3,15)=2.42, p=0.11).
SB-269970 does not block scopolamine-induced deficits
in the DNMTP task
The effect of SB-269970 (10 mg/kg, IP) on scopolamine
(0.06 mg/kg, IP) -induced deficits was evaluated in the DNMTP
task (Fig. 2). A two-way repeated measures ANOVA (delay x
treatment group), with repeated measures on delay, detected a
main effect of delay (F(4, 25)=2.79, p=0.048) and group (F(3,
75)=37.29, p=0.000005), but no interaction (F(12, 75)=0.88,
p=0.57). Duncan’s post-hoc tests on group revealed that
scopolamine worsened performance in both the vehicle-pretreat-
ed and SB-269970- pretreated groups (p,0.00006 comparing
vehicle + vehicle to vehicle + scopolamine and p,0.00005
comparing vehicle + vehicle to SB-269970 + scopolamine). SB-
269970 had no effect on its own (p=0.83, comparing vehicle +
vehicle to SB-269970 + vehicle), but augmented the deficit
caused by scopolamine (p,0.0003 comparing vehicle + scopol-
amine to SB-269970 + scopolamine). There was no difference in
the number of trials completed in each session among treatment
groups (F(3,15)=2.65, p=0.086).
SB-269970 blocks MK-801-induced glutamate efflux in
the cortex of freely moving rats
The effect of SB-269970 (10 mg/kg, IP) on MK-801 (0.1 mg/
kg, IP) induced glutamate efflux was evaluated in the cortex of
conscious rats using biosensor technology (Fig. 3.). A two-way
repeated measures ANOVA (group x time) revealed a main effect
of group (F(3, 26)=12.45, p=0.00003) and time (F(15,
390)=4.31, p=0.000005), and an interaction (F(45, 390)=4.34,
p=0.000005). Post-hoc tests revealed that the vehicle + MK-801
had higher glutamate concentrations compared to the vehicle +
vehicle group from 10–60 min (p=0.000001–0.04 at those time
points). SB-269970 did not affect glutamate levels per se (p.0.05
at all time points), but attenuated MK-801-induced increases in
glutamate (p,0.05 at 15 min, p,0.02 at 20 min, p,0.04 at
35 min, comparing SB-269970 + MK-801 to vehicle+MK-801).
Glutamate levels were only elevated in the SB-269970 + MK-801
group compared to the SB-269970 + vehicle group at 20 and
25 min (p,0.02 and p,0.04, respectively).
SB-269970 does not block MK-801-induced dopamine
extracellular levels in the cortex of freely moving rats
The effect of SB-269970 (10 mg/kg, IP) on MK-801 (0.1 mg/
kg, IP) induced dopamine extracellular levels was evaluated in
the cortex of conscious rats using microdialysis (Fig. 4.). A two-
way repeated measures ANOVA revealed a main effect of group
(F(3, 17)=21.18, p=0.00001) and time (F(11, 187)=45.27, p=
0.00005), and an interaction (F(33, 187)=13.89, p=0.00005).
Post-hoc tests revealed that the vehicle + MK-801 had higher
dopamine levels compared to the vehicle + vehicle group from
30 – 105 min (p=0.000004–0.000075 at those time points). SB-
269970 did not affect dopamine levels by itself, nor did it alter
the effect of MK-801 on dopamine levels (p.0.05 at all time
points).
SB-269970 does not change MK-801 plasma and brain
concentrations
MK-801 plasma and brain concentrations were determined
following intraperitoneal dosing of vehicle + MK-801 (0.1 mg/kg)
or co-administration of MK-801 (0.1 mg/kg) with SB-269970
(10 mg/kg). The concentration data was analyzed using a one
compartment model with WinNonlin to determine pharmacoki-
netic parameters (Table 2). A t-test was performed on the
pharmacokinetic parameters showed that SB-269970 did not
affect the kinetics of MK-801 (p.0.05 Table 2).
Table 1. Number of trials completed in the DNMTP task.
MK-801 (0.1 mg/kg) Scopolamine (0.06 mg/kg)
Vehicle +
Vehicle
Vehicle +
MK-801
SB-269970 +
MK-801
SB-269970 +
Vehicle
Vehicle +
Vehicle
Vehicle +
Scopolamine
SB-269970 +
Scopolamine
SB-269970 +
Vehicle
Number of trials 48664 6 685 3 654 0 654 4 654 3 643 5 685 3 65
SB-269970 (10 mg/kg) and MK-801 (0.1 mg/kg), or their vehicles, were co-administered 10 min before the beginning of the session. SB-269970 (10 mg/kg) and
scopolamine (0.06 mg/kg), or their vehicles, were administered 10 and 30 min, respectively, before the beginning of the session. There was no difference in the number
of trials completed in each session among treatment groups. Data are expressed as mean 6 S.E.M., N = 6 per group).
doi:10.1371/journal.pone.0020210.t001
Figure 2. Effects of SB-269970 on scopolamine-induced
DNMTP deficits. SB-269970 (10 mg/kg) and scopolamine (0.06 mg/
kg), or their vehicles, were administered 10 and 30 min, respectively,
before the beginning of the session (N=6 per group). SB-269970
augmented the deficit caused by scopolamine (*p,0.05, main effect).
For statistical details see the result section.
doi:10.1371/journal.pone.0020210.g002
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The results of the present work indicated that the selective 5-HT7
receptor antagonist SB-269970 reversed MK-801 but not scopol-
amine -induced cognitive deficit in the DNMTP task. In addition,
the 5-HT7 receptor antagonist normalized MK-801-induced glu-
tamate efflux but not MK-801-induced dopamine extracellular
levels in the cortex of freely moving rats. The pharmacokinetic
study showed that rat plasma and brain concentrations of MK-801
were not affected by co-administration of SB-269970.
The 5-HT7 receptor is expressed in brain regions involved in
learning and memory such as hippocampal formation and frontal
cortex [3]. Several reports in the literature suggest that it may play
a role in the control of learning and memory processes [16,34,
35,36]. In this study we evaluated the effect of a selective 5-HT7
receptor antagonist in the DNMTP task, a translational assay
of working memory. As previously reported, MK-801 and scopola-
mine were found to decrease percent correct responding without
affecting the number of trials [20,37,38,39,40]. The selective 5-HT7
receptor antagonist, SB-269970, had no effect by itself on
percentage correct responding and number of trials. However,
SB-269970 significantly reversed MK-801 but not scopolamine-
induced memory deficits. The dose and pretreatment time of SB-
269970 selected for this study were based on previous studies where
itwasdemonstratedthatthe compound isbiologicallyactiveinother
behavioral assays [3,7,13,30]. For example, SB-269970 at a dose of
10 mg/kgwasfoundtoreduceimmobilitytimeinthetailsuspension
test and decrease REM sleep duration [7]. In the present study we
carried out a pharmacokinetic study to show that rat plasma
and brain concentrations of MK-801 were not affected by co-
administration ofSB-269970,demonstratingthat the effectobserved
in the DNMTP task is not confounded by a drug-drug interaction.
The reversal of MK-801 induced deficits by the 5-HT7 receptor
antagonist in the DNMTP task observed in the present study is
consistent with the study of Meneses showing that SB-269970
reversed MK-801-induced amnesia in the autoshapingPavlovian/
instrumental learning task [19]. In the later study, SB-269970 was
also found to reverse scopolamine -induced deficit in the same
procedure. In our study, using a different experimental paradigm,
SB-269970 was found to augment scopolamine -induced deficits in
the DNMTP task. It should be noted that the experimental
conditions were different between our study and Meneses’s study
and could have contributed to the contrasting findings. For
example, the dose of scopolamine was different (0.17 vs 0.06 mg/
kg in our study) and a different strain of rat was used (Wistar in
Meneses’s study vs Sprague-Dawley in our study).In addition,
different forms of memory were being measured (consolidation
memory in the Meneses’s study, with drug effects measured
24 hours later, and working memory in the present study, with
drug effects measured during the test while the drugs were on
board). Interestingly, in the present study, SB-269970 shifted the
scolopamine delay-response curve straight down, even at the
longer delay, where the scolopamine animals were already per-
forming at 50%. Fifty percent represents chance performance, but
the SB-269970+scolopamine treated animals were performing at
36.5 and 34.1% at the two longest delays. Performance below
chance suggests the animals were specifically choosing the same
lever as presented at the start of thetrial, instead of the opposite
lever or choosing randomly. Such performance could represent an
inability to disengage attention from the first presented lever and
Figure 4. Effects of SB-269970 on MK-801-induced dopamine release. Results are expressed as percentage ofbaseline (mean 6 S.E.M., N=5-
6 per group). SB-269970 (10 mg/kg) did not affect dopamine levels by itself, nor did it alter the effect of MK-801 (0.1 mg/kg) on dopamine levels.
*p,0.001, at each time point compared to control.
doi:10.1371/journal.pone.0020210.g004
Figure 3. Effects of SB-269970 on MK-801-induced glutamate
efflux in the prefrontal cortex. Real-time measurements of
glutamate were conducted before and after compound administration.
Results are expressed as as mean 6 S.E.M of change in glutamate
concentrations (N=5–15 per group). SB-269970(10 mg/kg) did not
affect glutamate levels per se but attenuated MK-801(0.1 mg/kg)-
induced increases in glutamate efflux. *p,0.05, at each time point
comparing vehicle + MK-801 to vehicle + vehicle.
# p,0.05, at each
time point comparing SB-269970 + MK-801 to vehicle + MK-801.
doi:10.1371/journal.pone.0020210.g003
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effects of scolopamine. Such effects would not be observed in the
Meneses’s study, where consolidation memory was measured and
neither drug was on board during the subsequent test. Further
neurochemical investigations on the effect of SB-269970 on the
level of acetylcholine are needed to shed light on this finding.
Potential drug-drug interaction between SB-269970 and scopol-
amine should be investigated as well. On the other hand, it is also
possible that the 5-HT7 receptor has more of a modulatory
function, with positive or negative effects on memory performance
depending on the background state. Noteworthy, 5-HT7 receptor
antagonists were found to decrease the memory enhancing effects
of the 5-HT1A/7 agonist 8-OH-DPAT in the autoshapingPavlo-
vian/instrumental learning task to levels far below that of controls,
such that performance was even worse than in the vehicle-treated
controls [19]. While the 5-HT7 receptor antagonists had no effect
by themselves per se, they were able to worsen memory per-
formance, but only under the background of 5-HT1A/7 activation
(which by itself improved performance). Interestingly, in the same
study the 5-HT7 receptor antagonists were also able to reverse
amnesic-inducing effects while being inactive alone [19]. It was
hypothesized that under procognitive or amnesic conditions 5-
HT7 receptor activity would be unmasked, leading to a modula-
tory role in memory formation [19]. In fact, the mRNA expression
of the 5-HT7 receptor has been shown to be enhanced during
memory consolidation [36], suggesting that 5-HT7 receptor acti-
vity can be important to normal memory functions. In this study it
was also shown that an agonist of the 5-HT7 receptor (AS-19)
improved memory consolidation, while partially downregulating
5-HT7 mRNA expression, whereas amnesic-drugs strongly down-
regulated 5-HT7 mRNA expression. AS-19 reversed the effects of
the amnesic-drugs on both memory performance and mRNA
expression. Thus, it is possible that a nominal amount of 5-HT7
receptor activity is required for normal memory processes and that
5-HT7 receptor ligands can have procognitive or amnesic effects
(depending on the background level of 5-HT/5-HT7 activity) once
5-HT7 receptors are unmasked.
A recent study by Horiguchi and Meltzer [41] showed that
selective 5-HT7 antagonism had a procognitive effect on the PCP-
induced impairment in novel object recognition test, a rodent
model of declarative memory deficit in schizophrenia. In addition,
preferential 5-HT7 antagonism was also found to contribute to the
ability of the atypical antipsychotics drugs lurasidone and amisul-
pride to ameliorate the PCP-induced novel object recognition
deficit. Another recent study by Horisawa and colleagues also
showed that the selective 5-HT7 receptor antagonist (SB-656104)
and lurasidone reversed MK-801-induced learning impairment in
the Morris Water Maze test [42]. Consistent with these finding,
Gasbarri and colleagues demonstrated that 5-HT7 receptor
blockade enhanced memory retention in the radial maze task
[18]. In contrast to their previous results [19], Perez-Garcia and
Meneses suggested that 5-HT7agonism may promote memory in
the hypoglutamatergic rat brain [34]. However, information about
the selectivity and brain penetration of the 5-HT7 agonist (AS-19)
used in the later study is lacking, hampering the full interpretation
of these data [34]. Another study by Ballaz and colleagues showed
that a high dose of SB-269970 caused impairment in novel object
recognition in low but not high responder animals suggesting that
5-HT7 blockade removed phenotypic differences in novel object
discrimination performance [43]. The authors concluded that
these findings might indicate different levels of 5-HT7 receptor
activity, suggesting that the manner in which rats adapt to the
environment may be under the influence of the 5-HT7 receptor.
In the present study, biosensor and microdialysis studies in the
cortex of freely moving rats were conducted to further investigate
the neurochemical interaction between 5-HT7 and NMDA
receptors. The biosensor technique is very comparable to the
microdialysis technique and both are able to selectively monitor
glutamate levels in the extracellular space. Compared to micro-
dialysis, biosensors are slightly smaller, and may result in less
damage around the recording area, and offer a much greater time
resolution. Theoretically, both microdialysis and biosensors decrease
the concentration of glutamate around the recording area –
microdialysis by sampling and removing glutamate from the extra-
cellular fluid and biosensors by converting glutamate to alpha-
ketoglutarate. Another difference between the biosensor methods
and conventional microdialysis methods is that in microdialysis, the
animal is tethered so that tubing can deliver the CSF. In biosensor
studies, the animals are completely free moving and untethered, and
the biosensor signal is transmitted wirelessly. This may result in less
stress to the animal during testing. Using the biosensor technology,
MK-801 was found to increase glutamate efflux in the cortex in
agreement with the literature [32,44]. By itself SB-269970 did not
modify glutamate or dopamine extracellular levels in cortex. SB-
269970 was found to significantly reduce MK-801-induced gluta-
mate efflux. These effect were qualitatively similar to the results
obtained with the mGluR2/3 receptor agonist LY-379268 [44].
In contrast, SB-269970 did not modify MK-801 induced
dopamine extracellular levels in cortex indicating that blockade
of 5-HT7 receptors selectively reduced cortical glutamate outflow.
Collectively, the results from the present study indicated that a
selective 5-HT7 receptor antagonist might reverse cognitive deficits,
particularly those associated with NMDA receptor hypofunction,
by selectively normalizing glutamatergic neurotransmission. Selec-
tive 5-HT7 antagonism may represent a novel approach for im-
provement of cognitive impairments in schizophrenia, particularly
working memory.
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Table 2. Pharmacokinetic and blood brain barrier parameters
of MK-801 (0.1 mg/kg, IP) co-administered with vehicle or with
SB-269970 (10 mg/kg, IP).
Vehicle + MK-801 SB-269970 + MK-801
Plasma
Tmax (h) 0.31632% 0.31635%
Cmax (mM) 0.04614% 0.03619%
AUCinf (h mmol/L) 0.08633% 0.04625%
Brain
Tmax (h) 0.40620% 0.37628%
Cmax (mM) 0.28611% 0.20615%
AUCinf (h mmol/L) 0.60623% 0.33621%
Data are expressed as mean 6 coefficient variation (%) (N =4 per group).
doi:10.1371/journal.pone.0020210.t002
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